

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/784,674		02/15/2001	Karen W. Shannon	10971464-3	3167
22878	7590	05/12/2006		EXAMINER	
AGILENT	TECHN	OLOGIES, INC.	NEGIN, RUSSELL SCOTT		
INTELLEC'	TUAL PR	ROPERTY ADMINIS		5 - PER 14 10 ER	
P.O. BOX 7599				ART UNIT	PAPER NUMBER
M/S DL429				1631	
LOVELAND, CO 80537-0599				DATE MAILED: 05/12/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	09/784,674	SHANNON ET AL.				
Office Action Summary	Examiner	Art Unit				
	Russell S. Negin	1631				
The MAILING DATE of this communication app	ears on the cover sheet with the c	orrespondence address				
Period for Reply	VIC CET TO EVOIDE 2 MONTU	S) OD THIRTY (30) DAVS				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DATE of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period value for reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim will apply and will expire SIX (6) MONTHS from the cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 27 Fe	ebruary 2006.					
2a) ☐ This action is FINAL . 2b) ☑ This	action is non-final.					
,						
closed in accordance with the practice under E	Ex parte Quayle, 1935 C.D. 11, 45	i3 O.G. 213.				
Disposition of Claims						
4) Claim(s) 1,2,5-25,27-40 and 102-165 is/are pending in the application.						
4a) Of the above claim(s) is/are withdraw	wn from consideration.					
5) Claim(s) is/are allowed.						
6) Claim(s) 1,2,17-22,102-105,111-113,122-125,						
7) Claim(s) <u>5-16,23-40,106-110,114-121,126-130</u> 8) Claim(s) are subject to restriction and/o		ina 158-165 is/are objected to.				
are subject to restriction and/o	r election requirement.					
Application Papers						
9) The specification is objected to by the Examine						
10) ☐ The drawing(s) filed on is/are: a) ☐ acc						
Applicant may not request that any objection to the						
Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Ex						
Priority under 35 U.S.C. § 119						
12) ☐ Acknowledgment is made of a claim for foreigna) ☐ All b) ☐ Some * c) ☐ None of:	priority under 35 U.S.C. § 119(a))-(d) or (f).				
1. Certified copies of the priority document						
2. Certified copies of the priority document						
 Copies of the certified copies of the prior application from the International Bureau 	·	ed in this National Stage				
* See the attached detailed Office action for a list	*	ed.				
Attachment(s)	4) 🖂 Intention Sur-	(PTO 413)				
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) 	4) Interview Summary Paper No(s)/Mail D	ate				
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Informal F 6) Other:	Patent Application (PTO-152)				

DETAILED ACTION

This action is non-final. Claims currently pending are 1, 2, 5-25, 27-40 and 102-165.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The rejection of claims 1, 2, 5-25, 27-40 and 102-165 under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for contiguous sets of oligonucleotides in clusters, does not reasonably provide enablement for noncontiguous sets of nucleotides in clusters is withdrawn due to arguments made by the applicant in the remarks of February 27, 2006, pages 19-21.

Claim Objections

Claims 5-16, 23-40, 106-110, 114-121, 126-130, 133, 134, 141-145, 147, 153, 154 and 158-165 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the

unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1, 2, 17-22, 102-105, 111-113, 122-125, 131-132, 135-140, 146, 148-152, and 155-157 rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-6, 17-18, 20-21, 24, 41, 42, 46, 47, 60-61, 63-64, 72-77, 78, and 87-92 of U.S. Patent No. 6,251,588. Although the conflicting claims are not identical, they are not patentably distinct from each other because U.S. Patent No. 6,251,588 anticipates (i.e. are a species of) the set of claims in the instant application. For example, claim 78 of the reference patent anticipates claim 1 of the instant application with additional constraints (i.e. melting temperatures, free energy values).

However, all of the limitations of claim 1 of the instant applications are included within claim 78 of the reference patent. Likewise, the same logic holds truth when comparing claim 102 or 148 of the instant application with claim 1 of the reference patent. All of the limitations are met between the application and patent, but the patent

has additional constraints (i.e. a requirement for size of the oligonucleotide), making it a species of the corresponding claims in the instant application. The remaining pending claims are dependent from either claims 1, 102, 146, or 148 in the instant application and correspond to claims in the reference patent. However, these dependent claims are dependent from independent claims that are described to have the differences stated above.

An obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but an examined application claim is not patentably distinct from the reference claim(s) because the examined claim is either anticipated by, or would be obvious over, the reference claim(s). see, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985).

Conclusion

No Claim is allowed.

Papers related to this application may be submitted to Technical Center 1600 by facsimile transmission. Papers should be faxed to Technical Center 1600 via the central PTO Fax Center. The faxing of such pages must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993)(See 37 CFR § 1.6(d)). The Central PTO Fax Center Number is (571) 273-8300.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Russell Negin, Ph.D., whose telephone number is (571) 272-1083. The examiner can normally be reached on Monday-Friday from 7am to 4pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's Supervisor, Ardin Marschel, Ph.D., Supervisory Patent Examiner, can be reached at (571) 272-0718.

Any inquiry of a general nature or relating to the status of this application should be directed to Legal Instrument Examiner, Tina Plunkett, whose telephone number is (571) 272-0549.

Information regarding the status of the application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information on the PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

RSN; May 4, 2006

Deg 5/4/06

JOHN S. BRUSCA, PH.D PRIMARY EXAMINER

Buno 5 May 2006